Fruquintinib DDI Study With P-gp and BCRP Substrates

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-04-22. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: celllinesubject haseffectivelimited
  Phrases that lowered it: healthythe pharmacokineticsproductsmalethe effect
• Phase: 1 (lowers risk) · Design
• Primary purpose: other (lowers risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 8.9% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 18197 (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 71.0% (lowers risk) · Drug's FDA history
• Blinding: none (lowers risk) · Design
• Drug's FAERS reports before start: 231836 (raises risk) · Drug's FDA history
• Maximum age: 55 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 12 (lowers risk) · Sponsor's track record
• Disease area, psychiatry: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Fruquintinib Food Effect and Proton Pump Inhibitor Study NCT04645940 · started 2020 · scored riskier than 2% of active trials completed
• Fruquintinib CYP3A Inhibitor and Inducer Study NCT04557397 · started 2020 · scored riskier than 2% of active trials completed
• Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects NCT01955304 · started 2012 · scored riskier than 1% of active trials completed
• A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects NCT05843708 · started 2023 · scored riskier than 1% of active trials completed
• A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Impairment. NCT01266980 · started 2010 · scored riskier than 4% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.